Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.44 |
| ▸ | PRKCG | P05129 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | AKT2 | P31751 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203531 | 1.00 | TDP1 (0.49) | TDP1MEN1KMT2ACYP3A4KCNQ2 | |
| SCHEMBL6200008 | 1.00 | TDP1 (0.49) | TDP1MEN1KMT2ACYP3A4KCNQ2 | |
| SCHEMBL6203533 | 1.00 | TDP1 (0.49) | TDP1MEN1KMT2ACYP3A4KCNQ2 | |
| SCHEMBL6485431 | 0.92 | TDP1 (0.46) | TDP1CYP3A4LMNAROCK1ROCK2 | |
| SCHEMBL6485420 | 0.92 | TDP1 (0.46) | TDP1CYP3A4LMNAROCK1ROCK2 | |
| SCHEMBL6485417 | 0.92 | TDP1 (0.46) | TDP1CYP3A4LMNAROCK1ROCK2 | |
| SCHEMBL6203363 | 0.92 | TDP1 (0.46) | TDP1CYP3A4LMNAROCK1ROCK2 | |
| SCHEMBL6204160 | 0.91 | TDP1 (0.48) | TDP1MEN1KMT2ACYP3A4KCNQ2 | |
| SCHEMBL6221619 | 0.91 | TDP1 (0.48) | TDP1MEN1KMT2ACYP3A4KCNQ2 | |
| SCHEMBL6221611 | 0.91 | TDP1 (0.48) | TDP1MEN1KMT2ACYP3A4KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900210-B2 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | claimed |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-27 | — | — | US | claimed |
| EP-1581498-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6900210-B2 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2004047739-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | KCNQ5, KCNQ2, KCNQ3 | TDP1 4075/4885MEN1 1209/4885KMT2A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.